Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma

• Published in: Journal of clinical oncology Vol. 27; no. 32; pp. 5452 - 5458
• Main Authors: O'DAY, Steven, GONZALEZ, Rene, LAWSON, David, WEBER, Robert, HUTCHINS, Laura, ANDERSON, Clay, HADDAD, Jonathan, KONG, Steven, WILLIAMS, Anthony, JACOBSON, Eric
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Society of Clinical Oncology 10.11.2009
• Subjects: Adult; Aged; Aged, 80 and over; Anemia - chemically induced; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Constipation - chemically induced; Cross-Over Studies; Dermatology; Double-Blind Method; Drug Administration Schedule; Fatigue - chemically induced; Female; Humans; Hydrazines - administration & dosage; Hydrazines - adverse effects; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Medical sciences; Melanoma - drug therapy; Melanoma - pathology; Middle Aged; Nausea - chemically induced; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Paclitaxel - therapeutic use; Treatment Outcome; Tumors; Tumors of the skin and soft tissue. Premalignant lesions; Antineoplastic agent; Malignant tumor; Metastasis; Randomized controlled trial; Cancerology; Taxane derivatives; Phase II trial; Malignant melanoma; Paclitaxel; Advanced stage; Antimitotic; Comparative study; Cancer

Elesclomol is a novel, small-molecule, oxidative stress inducer believed to exert selective cytotoxicity by increasing intracellular concentrations of reactive oxygen species, which results in cell death via mitochondrial apoptosis. We evaluated whether the addition of elesclomol to weekly paclitaxe...